Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall survival (OS)...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	NPJ precision oncology Ročník 9; číslo 1; s. 24 - 7
Hlavní autori:	Patel, Sandip P., Cano-Linson, Eleanor, Chae, Young Kwang, Schokrpur, Shiruyeh, Lao, Christopher D., Powers, Benjamin C., Victor, Adrienne I., Onitilo, Adedayo A., Shin, Sarah, Takebe, Naoko, Threlkel, Sara, McLeod, Christine M., Chen, Helen X., Sharon, Elad, Othus, Megan, Ryan, Christopher W., Blanke, Charles D., Kurzrock, Razelle
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 24.01.2025 Nature Publishing Group Nature Portfolio
Predmet:	692/308/409 692/4028/67/1813/1349 Cancer Research Diarrhea Gene Therapy Human Genetics Immunotherapy Internal Medicine Lung cancer Medical research Medicine Medicine & Public Health Metastasis Monoclonal antibodies Oncology Patients Skin cancer Targeted cancer therapy Toxicity Tumors
ISSN:	2397-768X, 2397-768X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!